Lasmiditan dosed at 100 mg or 200 mg is associated with greater odds of achieving pain freedom from migraine attacks compared with placebo, according to results from phase 3 study CENTURION presented at the PAINWeek 2020 Live Virtual Conference.
The CENTURION study (ClinicalTrails.gov Identifier: ClinicalTrials.gov Identifier: NCT02439320) analyzed the efficacy, safety, and consistency of response to lasmiditan in the treatment for adults with migraine, with or without aura, across 4 attacks. The study randomized 1471 participants with migraine to receive at least 1 dose of either lasmiditan 200 mg (n=486), lasmiditan 100 mg (n=485) or a control treatment, placebo for some participants, (n=500). Migraine attacks were treated by participants when pain was at least of moderate severity within 4 hours after initial onset.
Primary efficacy endpoints included measurement for pain freedom at 2 hours for the first attack and pain freedom at 2 hours for 2 of 3 attacks. Secondary endpoints included pain freedom at 60 minutes, sustained pain freedom at 24 and 48 hours, and pain relief at 1 and 2 hours. Results were self-recorded by patients into an electronic diary at 30 and 60 minutes as well as 2, 4, 6, 24, and 48 hours after dosing.
Participants who received lasmiditan 200 mg were 4.6 times more likely to achieve pain freedom at 2 hours when compared with those who received placebo (29.3% vs 8.4%; odds ratio [OR], 4.6; P <.001). Study participants randomized to receive lasmiditan 100 mg were 3.8 times more likely to achieve pain freedom at 2 hours when compared with those who received placebo (25.8% vs 8.4%; P <.001).
At 24 hours, participants who received lasmiditan 200 mg were 4.7 time more likely to reach sustained pain freedom when compared with those who received placebo (17.3% vs 4.3%; P <.001). Those receiving lasmiditan 100 mg were 3.5 times more likely to receive pain freedom when compared with those who received placebo (13.6% vs 4.3%; P <.001).
Participants receiving lasmiditan 200 mg were 4.1 times more likely to achieve sustained pain freedom at 48 hours when compared with those who received placebo (15.4% vs 4.3%; P <.001).
One in 5 participants noted that their migraine did not interfere with activities of daily living 2 hours after receiving lasmiditan (19.8% for those receiving 200 mg and 18.6% for those receiving 100 mg).
Disclosure: The CENTURION clinical trial was funded by Eli Lilly and Company.
Reyvow (lasmiditan) C-V demonstrated pain freedom from migraine attacks at 60 minutes and up to 48 hours in new phase 3 study. News release. Eli Lilly and Company; September 11, 2020. Accessed September 14, 2020. https://investor.lilly.com/news-releases/news-release-details/reyvowtm-lasmiditan-c-v-demonstrated-pain-freedom-migraine
This article originally appeared on Clinical Pain Advisor